Eurobio Scientific Discusses Breast Cancer Treatment Guidance at ESMO Symposium
Eurobio Scientific has shared information from a presentation on breast cancer treatment, featuring data on how EndoPredict can guide chemotherapy decisions for premenopausal women.
Eurobio Scientific has disseminated information following a presentation at the European Society for Medical Oncology (ESMO) Industry Satellite Symposium 2022, focusing on breast cancer treatment strategies.
The company highlighted findings related to the EndoPredict test, a tool designed to help oncologists determine the need for chemotherapy. The presentation aimed to showcase how the test can assist in making informed decisions, potentially avoiding overtreatment.
Key insights were presented by Dr. Anastasia Constantinidou, who shared data from the ESMO 2022 Congress. Her findings demonstrated the utility of EndoPredict in guiding treatment choices for premenopausal women diagnosed with early-stage ER+/HER2- breast cancer.
This initiative aligns with the growing trend towards personalized medicine in oncology, where diagnostic tools play a crucial role in tailoring treatments to individual patient profiles, thereby optimizing outcomes and minimizing adverse effects.